BIOTECHNOLOGY company Silence Therapeutics has appointed Tim Freeborn as FD.
Freeborn qualified as a chartered accountant with Arthur Goddard & Co, specialising in corporate tax. He then spent 12 years as a finance journalist at the Daily Mail before spending two years editing the Penny Shares Guide. He also wrote part-time for Shares Magazine.
In 2004, Freeborn joined Evolution Securities as an analyst, focusing on renewables and alternative energy, before he joined Xcap Securities in 2009, becoming head of research.
“Silence’s area of biotech is moving incredibly quickly. The company could play a big role and I’m delighted to be joining at this time,” he said.
Former CIoT president Stephen Coleclough was sentenced to 14 months in prison, suspended for two years.
According to Robert Half’s annual FTSE 100 CEO Tracker, one in four FTSE 100 bosses hold accounting qualifications
Deloitte to divest transactional property teams by 31 May after conflicts with audit operation
Tax vacancies rose by 11% in London and the south east during Q1 of 2016, compared to the same period last year.